MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGENMaster Development and License Agreement • November 9th, 2016 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated August 24, 2016 (the “Effective Date”) between SunGen Pharma LLC, CCIT Lab 124, 675 US Highway One, North Brunswick, NJ 08902, USA (SunGen) and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey, USA (“Elite”); SunGen and Elite may sometimes hereinafter be referred to as a “Party” or collectively as the “Parties”.
Re: Third Amendment to TPN-Elite Manufacturing and Supply Agreement dated June 23, 2011 and First Amendment to TPN-Elite Manufacturing and Supply Agreement dated September 21, 2012 and Second Amendment to TPN-Elite Manufacturing and Supply Agreement...Elite Pharmaceuticals Inc /Nv/ • November 9th, 2016 • Pharmaceutical preparations
The PharmaNetwork, LLC, a New Jersey limited liability company and its wholly owned subsidiary, Ascend Laboratories, LLC (together "TPN"), and Elite Pharmaceuticals, Inc., a Nevada corporation, and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a Delaware corporation (together "ELITE") are parties to a Manufacturing and Supply Agreement effective as of June 23, 2011 and a First Amendment of the Manufacturing and Supply Agreement dated September 21, 2012 and to a Second Amendment to TPN-Elite Manufacturing and Supply Agreement dated January 19, 2015 (together the “Agreement”). All capitalized terms used without definition in this letter agreement have the respective meanings provided in the Agreement.
August 9, 2016Elite Pharmaceuticals Inc /Nv/ • November 9th, 2016 • Pharmaceutical preparations
